long intergenic non-protein coding RNA 2059Genealiases: []
Q-omics provides the consensus-scored LINC02059 profile across patient tissues and cancer cell-line models. LINC02059 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, LINC02059 is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, LINC02059 RNA expression shows 6,147 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LGG, COAD, and PDAC as cancer lineages where LINC02059 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02059 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02059 survival associations across molecular data types. LINC02059 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02059 RNA expression–survival associations across cancer types. High LINC02059 expression shows unfavorable associations in LGG, PAAD, KIRP, READ, ACC and ESCA. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for LINC02059 RNA expression.
This table summarizes LINC02059 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02059. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02059 shows lower tumor expression in COAD. The COAD box plot shows higher LINC02059 RNA expression in normal versus tumor tissue (log2 FC = −0.009, t-test p = .017).
This table shows molecular features associated with LINC02059 in patient tissues and cancer cell lines. In patient samples, LINC02059 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
